STALICLA Translates Its Novel Precision Medicine Approach For Autism Spectrum Disorder Into Clinical Development In Phase 1b Trial Of STP1

Biotech company STALICLA has enrolled the first participant in its Phase 1b clinical trial with STP1, a first-in-class precision medicine for people within the autism spectrum disorder (ASD) Phenotype 1 subgroup (ASD-Phen1), a novel biological subgroup identified by STALICLA’s proprietary discovery platform. STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders (NDDs) currently diagnosed based on core behavioral features, including persistent deficits in social communication and . . .